/AGIO
AGIO Stock - Agios Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$24.46-1.09%
$0.27 (-1.09%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.11
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+50.2%upside
Target: $36.74
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AGIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$24.22 – $24.70
TARGET (TP)$36.75
STOP LOSS$22.50
RISK/REWARD1:6.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.86
52W High$46.00
52W Low$22.24
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $36.50M | $26.82M | $14.24M | N/A | N/A |
| Gross Profit | $32.33M | $17.32M | $12.54M | $-18,777,000 | $-18,772,000 |
| Gross Margin | 88.6% | 64.6% | 88.0% | N/A | N/A |
| Operating Income | $-425,737,000 | $-391,487,000 | $-389,047,000 | $-378,418,000 | $-335,916,000 |
| Net Income | $673.73M | $-352,088,000 | $-231,801,000 | $1.60B | $-327,370,000 |
| Net Margin | 1845.9% | -1312.6% | -1627.8% | N/A | N/A |
| EPS | $11.86 | $-6.33 | $-4.23 | $-6.36 | $-4.74 |
Company Overview
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
86%
Hold / Neutral
1
14%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish1 Neutral/Bearish
Price Targets
$42
Average Target
↑ 70.2% Upside
Now
$28
Low
$42
Average
$58
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Initiation | Buy | - |
| November 20th 2025 | Leerink Partners | Upgrade | Outperform | $34 |
| November 19th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $28 |
| February 24th 2025 | H.C. Wainwright | Initiation | Buy | $58 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| October 10th 2024 | Raymond James | Resumed | Outperform | $51 |
| September 27th 2024 | Leerink Partners | Downgrade | Market Perform | $56← $60 |
| February 8th 2024 | Cantor Fitzgerald | Initiation | Overweight | - |
| February 3rd 2023 | Piper Sandler | Initiation | Overweight | $41 |
| November 17th 2022 | Goldman | Upgrade | Neutral | $32← $17 |
| July 27th 2022 | SVB Leerink | Upgrade | Outperform | $33 |
Earnings History & Surprises
AGIOBeat Rate
67%
Last 18 quarters
Avg Surprise
+7.2%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-1.78
Q4 2025
EPS Surprise History
Q1 24
-4.9%
$-1.72vs$-1.64
Q2 24
+11.6%
$-1.45vs$-1.64
Q3 24
-7.0%
$-1.69vs$-1.58
Q4 24
-74.8%
$4.20vs$16.69
Q1 25
-3.0%
$-1.74vs$-1.69
Q2 25
+13.9%
$-1.55vs$-1.80
Q3 25
-10.9%
$-1.93vs$-1.74
Q4 25
+7.8%
$-1.78vs$-1.93
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $-1.96 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-1.93 | $-1.78 | +7.8% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-1.74 | $-1.93 | -10.9% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-1.80 | $-1.55 | +13.9% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-1.69 | $-1.74 | -3.0% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $16.69 | $4.20 | -74.8% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-1.58 | $-1.69 | -7.0% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-1.64 | $-1.45 | +11.6% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $-1.64 | $-1.72 | -4.9% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-1.69 | $-1.64 | +3.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-1.60 | $-1.51 | +5.6% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-1.72 | $-1.47 | +14.5% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-1.59 | $0.67 | +142.1% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.75 | $-1.49 | +14.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-1.78 | $-1.68 | +5.6% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.85 | $-1.74 | +5.9% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-1.71 | $-1.81 | -5.8% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-1.61 | $-1.48 | +8.1% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $-1.39 | $-1.36 | +2.2% | ✓ BEAT |
Latest News
The FDA Has Not Yet Issued Regulatory Decision On Agios Pharmaceuticals' Supplemental New Drug Application For Mitapivat For Adult Patients With Non-transfusion-dependent And Transfusion-dependent Alpha- Or Beta-thalassemia, And It Remains Under Review.
➖ NeutralBenzinga•Dec 8, 2025, 12:10 PM
Citigroup Initiates Coverage On Agios Pharmaceuticals with Buy Rating, Announces Price Target of $38
📈 PositiveBenzinga•Nov 26, 2025, 06:42 PM•Also:
Truist Securities Initiates Coverage On Agios Pharmaceuticals with Buy Rating, Announces Price Target of $32
📈 PositiveBenzinga•Nov 24, 2025, 05:49 PM
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $20
➖ NeutralBenzinga•Nov 21, 2025, 07:19 PM
Agios Pharmaceuticals shares are trading higher after Leerink Partners upgraded the stock from Market Perform to Outperform. The stock may also be rebounding after falling Wednesday on Phase 3 RISE UP trial data.
📈 PositiveBenzinga•Nov 20, 2025, 07:54 PM
Agios rebounds as Leerink upgrades to Outperform on selloff
📈 PositiveSeeking Alpha•Nov 20, 2025, 04:16 PM
RBC Capital Downgrades Agios Pharmaceuticals to Sector Perform, Lowers Price Target to $28
📉 NegativeBenzinga•Nov 20, 2025, 02:56 PM
B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $32
➖ NeutralBenzinga•Nov 20, 2025, 12:51 PM
Leerink Partners Upgrades Agios Pharmaceuticals to Outperform, Lowers Price Target to $34
📈 PositiveBenzinga•Nov 20, 2025, 12:50 PM
Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $25
➖ NeutralBenzinga•Nov 20, 2025, 12:48 PM
HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $48
➖ NeutralBenzinga•Nov 20, 2025, 10:08 AM
Agios falls after mixed data from late-stage trial for sickle cell therapy
📉 NegativeSeeking Alpha•Nov 19, 2025, 12:59 PM
Agios Pharmaceuticals shares are trading lower after the company reported topline Phase 3 RISE UP results showing mitapivat met the primary hemoglobin response endpoint but did not achieve statistical significance on sickle cell pain crises.
📉 NegativeBenzinga•Nov 19, 2025, 12:19 PM
Agios Pharmaceuticals Says Topline Results From RISE UP Phase 3 Trial Of Mitapivat For Sickle Cell Disease Met Its Primary Endpoint Of Hemoglobin Response, While Mitapivat Did Not Achieve Statistical Significance On The Annualized Rate Of Sickle Cell Pain Crises Compared To Placebo
➖ NeutralBenzinga•Nov 19, 2025, 12:06 PM
Agios Pharmaceuticals Q3 EPS $(1.78) Beats $(1.91) Estimate, Sales $12.880M Beat $10.417M Estimate
📈 PositiveBenzinga•Oct 30, 2025, 10:35 AM
Reported Earlier: Agios Pharmaceuticals Receives CHMP's Opinion For The New Indication For PYRUKYND; The European Commission Will Now Review The CHMP's Opinion, With The Final Decision Expected By Early 2026
📈 PositiveBenzinga•Oct 17, 2025, 03:27 PM
HC Wainwright & Co. Reiterates Buy on Agios Pharmaceuticals, Maintains $56 Price Target
📈 PositiveBenzinga•Sep 4, 2025, 04:04 PM
Agios Pharmaceuticals shares are trading lower after the company said the FDA extended the PDUFA goal date for PYRUKYND by three months to Dec. 7.
📉 NegativeBenzinga•Sep 4, 2025, 11:49 AM
Agios Pharmaceuticals Announces PDUFA Goal Date For PYRUKYND Extended By Three Months To Dec. 7
📉 NegativeBenzinga•Sep 4, 2025, 11:45 AM
Agios drops as FDA delays review of thalassemia drug
📉 NegativeSeeking Alpha•Sep 4, 2025, 11:30 AM
Frequently Asked Questions about AGIO
What is AGIO's current stock price?
Agios Pharmaceuticals, Inc. (AGIO) is currently trading at $24.46 per share. The stock has moved -1.09% today.
What is the analyst price target for AGIO?
The average analyst price target for AGIO is $36.75, based on 1 analyst.
What sector is Agios Pharmaceuticals, Inc. in?
Agios Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AGIO's market cap?
Agios Pharmaceuticals, Inc. has a market capitalization of $1.43 billion, making it a small-cap company.
Does AGIO pay dividends?
No, Agios Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
SRPT
Sarepta Therapeutics, Inc.
$21.04
Mkt Cap: $2.1B
Explore stocks similar to AGIO for comparison